ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Louisiana » Pulmonary Disease

Top Pulmonary Disease Prescribers in Louisiana

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
BARRY TILLMAN M.D.

Pulmonary Disease

31,427

$1.63M

1282
1020 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

18%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 56%

$52
Average prescription price

Avg: $156

CHARLES SMITH III M.D.

Pulmonary Disease

11,438

$883K

754
678 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 56%

$77
Average prescription price

Avg: $156

LEONARD GLADE M.D.

Pulmonary Disease

9,298

$955K

640
498 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 56%

$103
Average prescription price

Avg: $156

FRANCISCO CANDAL MD

Pulmonary Disease

7,032

$513K

504
402 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 56%

$73
Average prescription price

Avg: $156

KIRIT PATEL M.D.

Pulmonary Disease

6,707

$464K

401
310 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 56%

$69
Average prescription price

Avg: $156

DENNIS DALE MD

Pulmonary Disease

6,340

$661K

547
441 are 65+

2%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 56%

$104
Average prescription price

Avg: $156

RICHARD FEI M.D. F.C.C.P.

Pulmonary Disease

5,393

$1.15M

513
407 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 56%

$213
Average prescription price

Avg: $156

GLENN GOMES M.D.

Pulmonary Disease

5,058

$833K

549
434 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

51%
prescriptions for brand name drugs

Avg: 56%

$165
Average prescription price

Avg: $156

BOGDAN NOWAKOWSKI MD

Pulmonary Disease

4,641

$348K

424
273 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 56%

$75
Average prescription price

Avg: $156

MARK HODGES MD

Pulmonary Disease

4,335

$562K

487
414 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 56%

$130
Average prescription price

Avg: $156

GARY KOHLER MD

Pulmonary Disease

4,070

$726K

323
266 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 56%

$178
Average prescription price

Avg: $156

MAAN YOUNES M.D.

Pulmonary Disease

4,043

$1M

512
373 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 56%

$249
Average prescription price

Avg: $156

WILLIAM EMORY MD

Pulmonary Disease

3,609

$439K

373
328 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 56%

$122
Average prescription price

Avg: $156

BEN THOMPSON MD

Pulmonary Disease

3,546

$453K

328
285 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 56%

$128
Average prescription price

Avg: $156

JAMES MCCULLOUGH M.D.

Pulmonary Disease

3,513

$786K

541
483 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 56%

$224
Average prescription price

Avg: $156

MICHAEL MCCARTHY MD

Pulmonary Disease

3,349

$597K

344
294 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 56%

$178
Average prescription price

Avg: $156

JAMES HALES DO, FCCP, DABSM

Pulmonary Disease

2,994

$565K

373
254 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 56%

$189
Average prescription price

Avg: $156

MARSHALL IRBY M.D.

Pulmonary Disease

2,950

$373K

347
284 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 56%

$126
Average prescription price

Avg: $156

GREGORY ARDOIN M.D.

Pulmonary Disease

2,896

$721K

368
272 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 56%

$249
Average prescription price

Avg: $156

JOSE SANTIAGO M.D.

Pulmonary Disease

2,551

$444K

333
262 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 56%

$174
Average prescription price

Avg: $156

THOMAS SMITH M.D.

Pulmonary Disease

2,447

$349K

286
245 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 56%

$143
Average prescription price

Avg: $156

CLIFFORD BURNS MD

Pulmonary Disease

2,427

$314K

333
272 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 56%

$129
Average prescription price

Avg: $156

RALPH BOURGEOIS M.D.

Pulmonary Disease

2,401

$383K

329
264 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 56%

$160
Average prescription price

Avg: $156

STEPHANIE MCGRATH MD

Pulmonary Disease

2,329

$535K

257
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

87%
prescriptions for brand name drugs

Avg: 56%

$230
Average prescription price

Avg: $156

KATHERINE ST AMANT MD

Pulmonary Disease

2,269

$391K

268
205 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 56%

$173
Average prescription price

Avg: $156

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank